[
  {
    "ts": null,
    "headline": "Tracking Christopher Davis' Davis Selected Advisers 13F Portfolio - Q1 2025 Update",
    "summary": "Davis Selected Advisersâ 13F portfolio value increased to $17.35B, with the number of holdings rising from 100 to 104. Learn more about the portfolio here.",
    "url": "https://finnhub.io/api/news?id=ad893fda7efff23edddd51ef47b42c28e4a61952dee0627cf6e215442dd95b5d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747166969,
      "headline": "Tracking Christopher Davis' Davis Selected Advisers 13F Portfolio - Q1 2025 Update",
      "id": 134425396,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1200139358/image_1200139358.jpg?io=getty-c-w1536",
      "related": "DGX",
      "source": "SeekingAlpha",
      "summary": "Davis Selected Advisersâ 13F portfolio value increased to $17.35B, with the number of holdings rising from 100 to 104. Learn more about the portfolio here.",
      "url": "https://finnhub.io/api/news?id=ad893fda7efff23edddd51ef47b42c28e4a61952dee0627cf6e215442dd95b5d"
    }
  },
  {
    "ts": null,
    "headline": "Is Quest Diagnostics Incorporated's (NYSE:DGX) Recent Stock Performance Influenced By Its Fundamentals In Any Way?",
    "summary": "Quest Diagnostics (NYSE:DGX) has had a great run on the share market with its stock up by a significant 7.3% over the...",
    "url": "https://finnhub.io/api/news?id=9b1200410ee1419b5938e24a62a3cfe8b0a009fa1ac7eef99ebd70c36be04e5c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747158510,
      "headline": "Is Quest Diagnostics Incorporated's (NYSE:DGX) Recent Stock Performance Influenced By Its Fundamentals In Any Way?",
      "id": 134410201,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "Quest Diagnostics (NYSE:DGX) has had a great run on the share market with its stock up by a significant 7.3% over the...",
      "url": "https://finnhub.io/api/news?id=9b1200410ee1419b5938e24a62a3cfe8b0a009fa1ac7eef99ebd70c36be04e5c"
    }
  },
  {
    "ts": null,
    "headline": "Should You Continue to Retain DGX Stock in Your Portfolio?",
    "summary": "Quest Diagnostics continues to stay on investors' radars due to its robust Advanced Diagnostics offerings and strength in acquisitions.",
    "url": "https://finnhub.io/api/news?id=ae74ab9a9d84f2924ba1bf0ea7de85e8f8ca38cb858ecffbc38357b6ea4f6f42",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747136880,
      "headline": "Should You Continue to Retain DGX Stock in Your Portfolio?",
      "id": 134410202,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "Quest Diagnostics continues to stay on investors' radars due to its robust Advanced Diagnostics offerings and strength in acquisitions.",
      "url": "https://finnhub.io/api/news?id=ae74ab9a9d84f2924ba1bf0ea7de85e8f8ca38cb858ecffbc38357b6ea4f6f42"
    }
  },
  {
    "ts": null,
    "headline": "Ave Maria Rising Dividend Fund Q1 2025 Commentary",
    "summary": "For the three months ended March 31, 2025, the total return on the Ave Maria Rising Dividend Fund was 3.77%.",
    "url": "https://finnhub.io/api/news?id=bd0004269a1c9fa2d060d464d1fded007a246da05777f5cfaef4bbb87aa66fdc",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747133100,
      "headline": "Ave Maria Rising Dividend Fund Q1 2025 Commentary",
      "id": 134400095,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1359132436/image_1359132436.jpg?io=getty-c-w1536",
      "related": "DGX",
      "source": "SeekingAlpha",
      "summary": "For the three months ended March 31, 2025, the total return on the Ave Maria Rising Dividend Fund was 3.77%.",
      "url": "https://finnhub.io/api/news?id=bd0004269a1c9fa2d060d464d1fded007a246da05777f5cfaef4bbb87aa66fdc"
    }
  },
  {
    "ts": null,
    "headline": "Oncologists Report Seeing More Advanced Cancers and Say Current Tests Are Not Catching Cancer Recurrence Early Enough, New Quest Diagnostics Report Finds",
    "summary": "Oncologists feel they are seeing more and more patients with advanced cancers, say screening barriers are the leading reason why, and worry that current tests may not catch cancer recurrence early enough, according to a new report, \"The Cancer Paradox: Oncologists' Perspectives on Barriers to Advanced Cancer Care and Recurrence Monitoring.\"",
    "url": "https://finnhub.io/api/news?id=c28908160778f474f8ab43f943bf06ec19eb6f99f16b5d462eeecce5a2c68ecb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747130580,
      "headline": "Oncologists Report Seeing More Advanced Cancers and Say Current Tests Are Not Catching Cancer Recurrence Early Enough, New Quest Diagnostics Report Finds",
      "id": 134410204,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "Oncologists feel they are seeing more and more patients with advanced cancers, say screening barriers are the leading reason why, and worry that current tests may not catch cancer recurrence early enough, according to a new report, \"The Cancer Paradox: Oncologists' Perspectives on Barriers to Advanced Cancer Care and Recurrence Monitoring.\"",
      "url": "https://finnhub.io/api/news?id=c28908160778f474f8ab43f943bf06ec19eb6f99f16b5d462eeecce5a2c68ecb"
    }
  }
]